One To Watch

Piramal

Company Overview

A Mumbai-headquartered pharma services conglomerate operating across CDMO, complex hospital generics, and consumer healthcare, with a declared ambition to double CDMO revenue and become a global leader in antibody-drug conjugate manufacturing by 2030. Piramal Pharma Limited is part of the broader Piramal Group and serves clients across more than 100 countries through 17 global development and manufacturing facilities. Its three business segments are Piramal Pharma Solutions (CDMO), Piramal Critical Care (complex hospital generics), and Piramal Consumer Healthcare (Indian OTC brands). The CDMO arm is ranked 13th largest globally and among the top three in India, a competitive position the company is actively working to strengthen.

Headquarters and Global Presence

Piramal Pharma is headquartered in Mumbai, India, within the wider Mumbai-based Piramal Group. Its manufacturing footprint spans India, the USA, Canada, and Europe, with significant API and finished dosage sites in Telangana and Aurora, Ontario, and solid oral dosage operations in Sellersville, Pennsylvania. The distribution network reaches more than 100 countries, giving the CDMO arm access to both large innovator pharma clients and emerging biotech sponsors globally.

Founding and History

Piramal Pharma traces its heritage through Nicholas Piramal India Ltd, an earlier incarnation that pursued generics partnerships with European counterparts including Siegfried Pharma and Norton Healthcare, and signed distribution arrangements with Boots Healthcare. The current CDMO-focused strategy took shape through a series of acquisitions: Ash Stevens, a Michigan-based API CDMO founded in 1962, was acquired in August 2016, extending Piramal's North American API capabilities. The Digwal, Telangana facility and the Aurora, Ontario site have since been scaled substantially, with the Aurora plant completing a CAD $30 million expansion and beginning commercial runs in 2022.

Therapy Areas and Focus

Piramal's CDMO business serves clients across oncology, rare diseases, and hospital critical care, with particular depth in highly potent compounds, where the regulatory and technical barriers are highest. The Critical Care segment concentrates on inhaled anesthetics and complex hospital generics for the US, European, and global markets. On the consumer side, the company targets Indian self-care with an established brand portfolio covering dermatology, contraception, and gastrointestinal health. The unmet need most central to Piramal's current investment thesis is in complex biologics and ADCs, where sponsor capacity remains constrained and outsourcing demand is rising sharply.

Technology Platforms and Modalities

Piramal Pharma Solutions covers the full drug development lifecycle: discovery chemistry, process development, clinical trial supply, and commercial-scale API and finished dosage manufacturing. Specialist capabilities include highly potent APIs, antibody-drug conjugate development and manufacture, sterile fill/finish, peptide synthesis, and potent solid oral dosage forms. The acquisition of controlling interest in Yapan Bio now adds large-molecule biologics and vaccine CDMO capabilities, extending the platform into a segment where Piramal previously had limited infrastructure. The ADC offering, in particular, is being positioned as a future revenue driver, with the company publicly targeting market leadership in ADC contract commercialization.

Key Pipeline and Programs

Piramal operates as a services business rather than a drug developer, so its "pipeline" is defined by service platforms and client-facing capabilities rather than proprietary clinical assets. The Yapan Bio subsidiary, consolidated in August 2026, adds biologics and vaccine CDMO capability, including large-molecule process development and manufacturing, which broadens the service set available under Piramal Pharma Solutions. Epirium Bio is an active development partner under an exclusive manufacturing arrangement covering API, intermediates, formulation development, and solid oral dosage forms for orphan drugs targeting mitochondrial dysfunction, running across three Indian sites.

Recent Developments

The most material move of 2026 was the consolidation of Yapan Bio: on 18 August 2026, Piramal exercised a call option to acquire an incremental 40.67% stake for Rs 76 crore (approximately $7.95 million), lifting its holding to 74% and converting Yapan Bio from an associate to a subsidiary. Together, these moves reflect a deliberate push to widen the technical scope of Piramal Pharma Solutions as it chases its 2030 revenue-doubling target.

Key Personnel

Piramal Pharma's leadership operates within the governance structure of the wider Piramal Group, though the research context does not name specific executives by title for the current period. The company's strategic direction, including the 3-2-1 financial target and the CDMO growth mandate, is set at group level and executed through the Piramal Pharma Solutions, Critical Care, and Consumer Healthcare divisional management teams.

Strategic Partnerships

The exclusive manufacturing partnership with Epirium Bio covers orphan drug programs targeting mitochondrial diseases, spanning API, intermediates, and solid oral dosage forms across three Indian facilities. Yapan Bio, now a 74%-owned subsidiary, further broadens the biologics and vaccine manufacturing capability available to external sponsors.

FAQ Section

Piramal has stated a 3-2-1 target: triple EBITDA, double revenue, and reduce the debt-to-EBITDA ratio to one by 2030, with the CDMO business specifically mandated to double. Within that, ADC contract commercialization has been identified as a priority growth segment, and the company has publicly targeted global market leadership in that niche. The Yapan Bio consolidation and the Ajinomoto collaboration are both consistent with this direction.

ADCs require potent-compound handling, bioconjugation, and sterile fill/finish capabilities in combination, a technically demanding bundle that relatively few CDMOs can offer end-to-end. Piramal already had highly potent API and fill/finish infrastructure, and the Ajinomoto collaboration fills the bioconjugation gap. As oncology drug developers accelerate ADC programs, outsourcing demand is rising faster than internal sponsor capacity can follow, making a credible ADC CDMO offer commercially attractive.

Before the consolidation, Piramal Pharma Solutions was primarily a small-molecule and potent-compound CDMO with limited large-molecule infrastructure. Yapan Bio, a Hyderabad-based biologics and vaccine CDMO, adds large-molecule process development and manufacturing to the portfolio, which is now integrated into the Piramal Pharma Solutions service offering. At Rs 76 crore (roughly $7.95 million) for a controlling 74% stake, the acquisition was capital-efficient relative to the capability it brings.

Announced in August 2020, the Epirium Bio arrangement is an exclusive manufacturing relationship covering orphan drugs targeting mitochondrial depletion and dysfunction, a rare disease mechanism with high unmet need and limited therapeutic options. Piramal provides API, intermediates, formulation development, and solid oral dosage manufacturing across three Indian sites. The partnership illustrates Piramal's strategy of building long-term client relationships in specialty segments rather than competing on commodity volume.

The CDMO business spans oncology, where ADC and highly potent API demand is concentrated, rare diseases through the Epirium collaboration and orphan drug manufacturing, and hospital critical care through inhaled anesthetics and injectable generics. The Consumer Healthcare segment addresses dermatology, contraception, and gastrointestinal health in the Indian OTC market. The broadening into biologics and vaccines via Yapan Bio extends the addressable base further into immunology and infectious disease manufacturing.

Piramal Pharma Solutions is ranked 13th largest CDMO globally and among the top three in India, a position built through organic capacity expansion and targeted acquisitions including Ash Stevens in North America. The current phase is one of active capability broadening: the Yapan Bio biologics addition, the Ajinomoto ADC collaboration, and the Sellersville OSD suite opening all occurred within the past 12 months. The 2030 strategic target of doubling CDMO revenue signals that management views the business as still early in its scaling trajectory.

Want to Update your Company's Profile?